This post is presented by our media partner Psychedelic News Wire
View the original article here.
Last week, Mount Sinai Health System announced that it had received a $5 million donation from the Bob & Renee Parsons Foundation, which changed its name to the Parsons Research Center for Psychedelic Healing. This follows the expansion of its psychedelic research center to a new location focused on supporting the center’s capacity to assist in clinical trials that involve compounds such as psilocybin, ketamine and MDMA, among others.
These drugs have attracted a lot of attention in research for their potential in helping manage symptoms of mental-health conditions such as anxiety, depression and PTSD.
The gift will also facilitate the expansion of the center’s capacity for research, therapy and therapist training. The new location is at 600 West 112th Street and will have individual treatment rooms as well as a group therapy room with features to allow for research, teaching and therapy supervision. Additionally, it will offer a view of streets that are lined by trees and large windows to bring in a lot of natural light.
The research center’s clinical director, Amy Lehrner, explained that this design embraced the importance of setting in therapeutic outcomes. She added that patients would feel safe when they entered the space, noting that natural light and views of nature communicated warmth and serenity.
This expansion demonstrates the commitment made by Mount Sinai to offer strong scientific vision and institutional resources, as well as helping to advance groundbreaking clinical trials.
The funds from the foundation also reflect an understanding that the times demand serious research and unwavering commitment to finding effective therapies for veterans, many of whom are living with conditions such as post-traumatic stress disorder, which are resistant to traditional treatment.
Bob Parsons, cofounder of the foundation and U.S. Marine Corps Vietnam war veteran, revealed that after decades of struggling with PTSD, it was psychedelic-assisted therapy that helped him heal.
Dr. Rachel Yehuda, director of the research center, stated that since 2021, the research center had made progress toward better understanding the therapeutic potential of psychotherapy involving psychedelics. She added that the U.S. Food and Drug Administration’s recent decision to reject the use of MDMA-assisted therapy had caused uncertainty on when and how psychedelic therapy would be made available to all.
Currently, the center is developing protocols for different studies, with researchers at Mount Sinai also carrying out studies on ketamine and psilocybin-assisted therapy for patients with intergenerational trauma and major depression. This is in addition to researching the effectiveness of MDMA-assisted therapy for individuals with eating disorders.
As academic institutions increase their involvement in psychedelic research, the work they do will help to supplement what publicly traded entities such as atai Life Sciences N.V. (NASDAQ: ATAI) are doing in their quest to develop psychedelic medicines.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
